甘肃黄芪对心肌病大鼠血管紧张素及心肌细胞结构的影响  

Effect of Radix astragali on angiotensin and myocardial structure of cardiomyopathy in rats

作　　者：余静[1] 王琼英[2] 汪汉卿[1] 

机构地区：[1]中国科学院兰州化物所甘肃省天然药物重点实验室,甘肃兰州730000 [2]兰州大学第二医院,甘肃兰州730030

出　　处：《中国医院药学杂志》2005年第10期908-909,共2页Chinese Journal of Hospital Pharmacy

基　　金：甘肃省科学事业费项目(编号:QS041-C33-17);甘肃省自然科学基金项目(编号:ZS031-A25-054-E)

摘　　要：目的:探讨了解甘肃黄芪对阿霉素诱导的心肌病大鼠血浆血管紧张素I(AngⅠ)、血管紧张素II(AngⅡ)的水平及心肌细胞结构的影响。方法:30只Wistar大鼠随机分3组:对照组即生理盐水组(n=10);阿霉素组(n=10);黄芪+阿霉素组(n=10)。用放射免疫分析法测定血浆AngⅠ、AngⅡ,光镜及透射电镜观察心肌病理变化。结果:阿霉素组AngⅡ水平较对照组升高显著(P<0.01),黄芪+阿霉素组血浆AngⅡ水平比阿霉素组低,差异有统计学意义(P<0.05);阿霉素组血浆AngⅠ水平较对照组降低显著(P<0.01);黄芪+阿霉素组血浆AngⅠ水平与阿霉素组相比增高有显著性(P<0.01)。黄芪可改善阿霉素引起的心肌细胞结构的损伤。结论:黄芪对阿霉素诱导的心肌病大鼠具有心脏保护作用。OBJECTIVE To determine levels of plasma angiotension Ⅰ （Ang Ⅰ）and angiotension Ⅱ （Ang Ⅱ ） on doxorubicin-induced cardiomyopathy in rats,and explore changes of these items and pathology of cadiocytes in doxorubicin-induced rats treated with extractive of Radix Astragali. METHODS Thirty Wistar rats were divided randomLy into 3 groups, i.e control group（n = 10）, doxorubiein group（n = 10） and Radix Astragali ＋ doxorubiein group（n = 10）. Plasma Ang Ⅰ and Ang Ⅱ were estimated by radio-immunoassay. Pathological changes of cadiocytes were observed by light microscope and transmission electron microscope. RESULTS The level of plasma Ang Ⅱ increased significantly in the doxorubicin group compared to that of the controls（P〈0. 01） as well as decreased in Radix Astragali ＋ doxorubicin group compared to that of doxorubicin group（P〈0. 05）. The level of plasma Ang Ⅰ was found to be significantly decreased in the doxorubicin group compared to that of the controls（P〈0. 01）. The concentration of Ang Ⅰ in rats treated with Radix Astragali ＋ doxorubicin was higher than that in the doxorubicin-induced rats（P〈0.01 ）. CONCLUSION These data suggeste that Radix Astragali could influence the levels of plasma angiotensions and protect myocardium on doxorubicininduced cardiomyopathy in rats.

关 键 词：黄芪 阿霉素 心肌病 大鼠 血管紧张素 心肌细胞结构 

分 类 号：R392-33[医药卫生—免疫学] R169.1[医药卫生—基础医学]